Bristol-Myers Squibb Company and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared

SG&A Spending: Bristol-Myers vs. Corcept

__timestampBristol-Myers Squibb CompanyCorcept Therapeutics Incorporated
Wednesday, January 1, 2014569900000034916000
Thursday, January 1, 2015500100000036949000
Friday, January 1, 2016500200000045240000
Sunday, January 1, 2017484900000062416000
Monday, January 1, 2018455100000081289000
Tuesday, January 1, 20194871000000100359000
Wednesday, January 1, 20207661000000105326000
Friday, January 1, 20217690000000122356000
Saturday, January 1, 20227814000000152848000
Sunday, January 1, 20237772000000184259000
Monday, January 1, 20248414000000
Loading chart...

In pursuit of knowledge

SG&A Spending Patterns: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. Bristol-Myers Squibb Company, a leader in the sector, has consistently demonstrated robust spending on Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, their SG&A expenses grew by approximately 36%, peaking in 2022. This reflects their aggressive market strategies and commitment to maintaining a competitive edge.

In contrast, Corcept Therapeutics Incorporated, a smaller player, has shown a remarkable increase in SG&A spending, with a staggering 428% rise over the same period. This surge underscores their strategic investments in growth and market penetration.

The juxtaposition of these two companies highlights the diverse approaches within the pharmaceutical industry, where size and strategy dictate financial priorities. As the market continues to evolve, these spending patterns offer a glimpse into the future trajectories of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025